JPWO2019138917A1 - 細胞外液量算出装置及び細胞外液量算出方法 - Google Patents
細胞外液量算出装置及び細胞外液量算出方法 Download PDFInfo
- Publication number
- JPWO2019138917A1 JPWO2019138917A1 JP2019564643A JP2019564643A JPWO2019138917A1 JP WO2019138917 A1 JPWO2019138917 A1 JP WO2019138917A1 JP 2019564643 A JP2019564643 A JP 2019564643A JP 2019564643 A JP2019564643 A JP 2019564643A JP WO2019138917 A1 JPWO2019138917 A1 JP WO2019138917A1
- Authority
- JP
- Japan
- Prior art keywords
- dialysis
- amount
- uric acid
- fluid volume
- extracellular fluid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003722 extracellular fluid Anatomy 0.000 title claims abstract description 217
- 238000004364 calculation method Methods 0.000 title claims abstract description 91
- 238000000502 dialysis Methods 0.000 claims abstract description 539
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 180
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 179
- 229940116269 uric acid Drugs 0.000 claims abstract description 179
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 106
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 348
- 239000004202 carbamide Substances 0.000 claims description 177
- 210000002381 plasma Anatomy 0.000 claims description 117
- 210000002977 intracellular fluid Anatomy 0.000 claims description 71
- 238000005534 hematocrit Methods 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 44
- 239000000126 substance Substances 0.000 claims description 36
- 230000017531 blood circulation Effects 0.000 claims description 23
- 210000001124 body fluid Anatomy 0.000 claims description 23
- 239000010839 body fluid Substances 0.000 claims description 23
- 210000000170 cell membrane Anatomy 0.000 claims description 13
- 239000012530 fluid Substances 0.000 claims description 8
- 210000001601 blood-air barrier Anatomy 0.000 claims description 7
- 229940045136 urea Drugs 0.000 description 171
- 239000002253 acid Substances 0.000 description 87
- 230000037396 body weight Effects 0.000 description 43
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 36
- 229910052708 sodium Inorganic materials 0.000 description 36
- 239000011734 sodium Substances 0.000 description 36
- 210000004369 blood Anatomy 0.000 description 28
- 239000008280 blood Substances 0.000 description 28
- 210000003205 muscle Anatomy 0.000 description 28
- 230000003834 intracellular effect Effects 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 18
- 230000007423 decrease Effects 0.000 description 16
- 230000037237 body shape Effects 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 206010030113 Oedema Diseases 0.000 description 9
- 210000000577 adipose tissue Anatomy 0.000 description 9
- 238000009792 diffusion process Methods 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 210000000663 muscle cell Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 206010019280 Heart failures Diseases 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 238000012937 correction Methods 0.000 description 6
- 230000003907 kidney function Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 238000011976 chest X-ray Methods 0.000 description 5
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 208000018578 heart valve disease Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 4
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 4
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 4
- 206010037423 Pulmonary oedema Diseases 0.000 description 4
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 235000003715 nutritional status Nutrition 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 208000005333 pulmonary edema Diseases 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 230000000322 hemodialysis Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010041925 Staphylococcal infections Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003617 erythrocyte membrane Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 208000001076 sarcopenia Diseases 0.000 description 2
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 101100338765 Danio rerio hamp2 gene Proteins 0.000 description 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 101150043052 Hamp gene Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- -1 urea Chemical compound 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
- A61M1/1603—Regulation parameters
- A61M1/1605—Physical characteristics of the dialysate fluid
- A61M1/1609—Physical characteristics of the dialysate fluid after use, i.e. downstream of dialyser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
- A61M1/1603—Regulation parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1621—Constructional aspects thereof
- A61M1/1647—Constructional aspects thereof with flow rate measurement of the dialysis fluid, upstream and downstream of the dialyser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
- A61M2205/3334—Measuring or controlling the flow rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/207—Blood composition characteristics hematocrit
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Vascular Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Fluid Mechanics (AREA)
- External Artificial Organs (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
なお、本発明者らが行なった臨床実験により、上記の細胞外液量算出装置10で採用している細胞外液量算出方法により算出された透析後の標準化細胞外液量を用いれば、患者の細胞外液量が適正であるか否かを評価することが可能であることが確認されている。
また、本発明者らが行なった実験では、細胞内液量を算出することによって、透析患者の筋肉量を評価可能であることが確認されている。上述したように、細胞内液量は、筋肉量の増減を反映して増減する。そこで、透析患者の体重が変化していない場合であっても、細胞内液量が減少している場合には、透析患者の筋肉量が減少していると推定することができる。すなわち、細胞内液量を算出することによって、透析患者がサルコペニア(葛谷雅文:超高齢社会におけるサルコペニアとフレイル. 日内会誌 104: 2602-2607, 2015)であることを早期に発見することができる。
Claims (7)
- 透析前の血漿尿酸濃度と、透析後の血漿尿酸濃度と、透析による尿酸除去量と、透析による除水量と、を取得可能に構成される第一の取得部と、
該第一の取得部で取得した該透析前の血漿尿酸濃度と該透析後の血漿尿酸濃度と該尿酸除去量と該除水量とに基づいて特定される、尿酸の透析前後の収支に基づいて、細胞外液量を算出する第一の演算部と、を備える、細胞外液量算出装置。 - ダイアライザの尿酸総括物質移動−面積係数と、ダイアライザの血液流通速度と、ダイアライザの透析液流通速度と、ヘマトクリット値と、を取得可能に構成される第二の取得部と、
該第二の取得部で取得した該尿酸総括物質移動−面積係数と、該血液流通速度と、該透析液流通速度と、該ヘマトクリット値に基づいて、尿酸クリアランスを算出する第二の演算部と、
前記第二の演算部により算出された前記尿酸クリアランスと、前記第一の取得部で取得した前記透析前の血漿尿酸濃度と前記透析後の血漿尿酸濃度に基づいて、前記尿酸除去量を算出する第三の演算部と、を備える、請求項1に記載の細胞外液量算出装置。 - 透析前の血漿尿素濃度と、透析後の血漿尿素濃度と、透析による尿素除去量と、を取得可能に構成される第三の取得部と、
該第三の取得部で取得した該透析前の血漿尿素濃度と、該透析後の血漿尿素濃度と、該尿素除去量と、前記第一の取得部で取得した前記透析による除水量とに基づいて、体内総体液量を算出する第四の演算部と、を備える、請求項1又は2に記載の細胞外液量算出装置。 - 前記第四の演算部において算出された体内総体液量から、前記第一の演算部において算出された細胞外液量を差し引いて、細胞内液量を算出する第五の演算部と、を備える、請求項3に記載の細胞外液量算出装置。
- 前記第五の演算部により算出された細胞内液量を用いて細胞外液量を補正する第六の演算部と、を備える、請求項4に記載の細胞外液量算出装置。
- 細胞外液量を算出する方法であって、
透析前の血漿尿酸濃度を取得する第一取得工程と、
透析後の血漿尿酸濃度を取得する第二取得工程と、
透析による尿酸除去量と、透析による除水量とを取得する第三取得工程と、
前記第一取得工程、前記第二取得工程及び前記第三取得工程によって取得した前記透析前血漿尿酸濃度と前記透析後血漿尿酸濃度と前記尿酸除去量と前記除水量とに基づいて特定される、尿酸の透析前後の収支に基づいて、透析後の細胞外液量を算出する算出工程と、を備える、細胞外液量算出方法。 - 細胞膜を通過不能であると共に毛細血管膜を通過可能な物質の透析前の血漿中の濃度である透析前物質濃度と、前記物質の透析後の血漿中の濃度である透析後物質濃度と、透析によって除去された前記物質の量である物質除去量と、透析による除水量と、を取得可能に構成される第一の取得部と、
該第一の取得部で取得した該透析前物質濃度と該透析後物質濃度と該物質除去量と該除水量とに基づいて特定される、前記物質の透析前後の収支に基づいて、細胞外液量を算出する第一の演算部と、を備える、細胞外液量算出装置。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018002171 | 2018-01-10 | ||
JP2018002171 | 2018-01-10 | ||
PCT/JP2018/048346 WO2019138917A1 (ja) | 2018-01-10 | 2018-12-27 | 細胞外液量算出装置及び細胞外液量算出方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2019138917A1 true JPWO2019138917A1 (ja) | 2020-12-24 |
JP7276155B2 JP7276155B2 (ja) | 2023-05-18 |
Family
ID=67218662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019564643A Active JP7276155B2 (ja) | 2018-01-10 | 2018-12-27 | 細胞外液量算出装置及び細胞外液量算出方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20200345916A1 (ja) |
EP (1) | EP3738624B1 (ja) |
JP (1) | JP7276155B2 (ja) |
CN (1) | CN111801124B (ja) |
WO (1) | WO2019138917A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210187178A1 (en) * | 2018-08-23 | 2021-06-24 | Nipro Corporation | Extracellular fluid volume calculator and method for calculating extracellular fluid volume |
WO2022172926A1 (ja) * | 2021-02-12 | 2022-08-18 | ニプロ株式会社 | 筋肉量算出装置及び筋肉量算出方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57183855A (en) * | 1981-05-01 | 1982-11-12 | Asahi Medical Co | Apparatus for measuring body liquid amount of inside and outside of cell and osmotic pressure in blood |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE513034C2 (sv) * | 1997-06-02 | 2000-06-19 | Gambro Lundia Ab | Metod och anordning för beräkning av dialyseffektivitet |
US6615077B1 (en) * | 2000-08-14 | 2003-09-02 | Renal Research Institute, Llc | Device and method for monitoring and controlling physiologic parameters of a dialysis patient using segmental bioimpedence |
DE60000544T2 (de) * | 2000-11-06 | 2003-02-27 | Fresenius Medical Care De Gmbh | Verfahren und Gerät zur Bestimmung des Trockengewichts eines Patienten mit Nierenversagen |
JP4123230B2 (ja) * | 2002-07-12 | 2008-07-23 | セイコーエプソン株式会社 | 血液中水分量検出装置及び血液透析時期判定装置 |
JP4726045B2 (ja) * | 2005-04-08 | 2011-07-20 | 日機装株式会社 | 血液透析装置 |
JP4822258B2 (ja) * | 2005-11-11 | 2011-11-24 | 日機装株式会社 | 血液透析装置 |
JP2008264217A (ja) * | 2007-04-20 | 2008-11-06 | Sekisui Chem Co Ltd | 血液透析評価方法及び血液透析評価装置 |
WO2010127136A2 (en) * | 2009-04-30 | 2010-11-04 | Pharmacophotonics, Inc. | Measurement of body fluid volumes |
EP2514449A4 (en) * | 2009-12-17 | 2015-06-24 | Nipro Corp | hemodialyzer |
JP5450818B2 (ja) * | 2010-07-14 | 2014-03-26 | 旭化成メディカル株式会社 | 血液透析システム |
WO2012051261A2 (en) * | 2010-10-15 | 2012-04-19 | Fresenius Medical Care Holdings, Inc. | Dry weight predictor |
US9061099B2 (en) * | 2011-04-29 | 2015-06-23 | Medtronic, Inc. | Cardiovascular monitoring for fluid removal processes |
JP5815981B2 (ja) * | 2011-05-10 | 2015-11-17 | ニプロ株式会社 | 透析装置 |
WO2013040082A2 (en) * | 2011-09-12 | 2013-03-21 | Medtronic, Inc. | Polystyrene sulfonate resin for use with a hemodialysis system having a controlled compliance dialysis circuit |
CN103998072B (zh) * | 2011-09-19 | 2018-02-06 | 弗雷森纽斯医疗护理控股有限公司 | 透析患者的干重量估计 |
CN102697522B (zh) * | 2012-06-01 | 2013-11-20 | 贝恩医疗设备(广州)有限公司 | 一种在线相对血容量检测装置及其检测方法 |
JP5641459B1 (ja) * | 2013-09-10 | 2014-12-17 | 学校法人加計学園 | 透析排液から患者の体液内の初期溶質量を決定する装置 |
DE102014104768A1 (de) * | 2014-04-03 | 2015-10-29 | B. Braun Avitum Ag | Vorrichtung und Verfahren zum Bestimmen eines Verteilungsvolumens bei einem Dialysepatienten |
CN204654896U (zh) * | 2015-05-21 | 2015-09-23 | 中国人民解放军第三军医大学第三附属医院 | 一种血容量变化比率计算尺 |
EP3302605B1 (en) * | 2015-05-25 | 2019-12-25 | Gambro Lundia AB | Apparatus for extracorporeal blood treatment i |
US10434236B2 (en) * | 2015-05-25 | 2019-10-08 | Gambro Lundia Ab | Extracorporeal blood treatment apparatus having dialysis fluid parameter data entry |
-
2018
- 2018-12-27 CN CN201880086257.XA patent/CN111801124B/zh active Active
- 2018-12-27 WO PCT/JP2018/048346 patent/WO2019138917A1/ja unknown
- 2018-12-27 JP JP2019564643A patent/JP7276155B2/ja active Active
- 2018-12-27 US US16/960,735 patent/US20200345916A1/en active Pending
- 2018-12-27 EP EP18900480.7A patent/EP3738624B1/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57183855A (en) * | 1981-05-01 | 1982-11-12 | Asahi Medical Co | Apparatus for measuring body liquid amount of inside and outside of cell and osmotic pressure in blood |
Also Published As
Publication number | Publication date |
---|---|
EP3738624A4 (en) | 2021-09-01 |
EP3738624A1 (en) | 2020-11-18 |
CN111801124B (zh) | 2023-05-23 |
EP3738624B1 (en) | 2022-09-14 |
CN111801124A (zh) | 2020-10-20 |
JP7276155B2 (ja) | 2023-05-18 |
WO2019138917A1 (ja) | 2019-07-18 |
US20200345916A1 (en) | 2020-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7072710B2 (en) | Method and a device for determining the dry weight of a patient with kidney failure | |
EP2874540B1 (en) | Calibration of a body parameter for monitoring dialysis | |
JP6384667B2 (ja) | 患者のドライウェイトを推定する方法 | |
JP7276155B2 (ja) | 細胞外液量算出装置及び細胞外液量算出方法 | |
JP5774993B2 (ja) | 肢切断患者の補正容積区画を量定する方法並びにこの方法を実施する装置及びコンピュータプログラム製品 | |
JP7218660B2 (ja) | 細胞外液量標準化装置、これを備える細胞外液量評価装置及び細胞外液量を標準化するためのコンピュータプログラム | |
Farokhi et al. | Applying bio-impedance vector analysis (BIVA) to adjust ultrafiltration rate in critically ill patients on continuous renal replacement therapy: a randomized controlled trial | |
CN110111871B (zh) | 一种基于动力学模型的干体重评估方法及系统 | |
JPWO2020040208A1 (ja) | 細胞外液量算出装置及び細胞外液量算出方法 | |
Valtuille | Bioimpedance to assess body composition in chronic kidney disease: When technology can help solve a clinical problem | |
WO2022172926A1 (ja) | 筋肉量算出装置及び筋肉量算出方法 | |
JP7495945B2 (ja) | 透析患者における物質の生成速度の推定 | |
JP2024067179A (ja) | 細胞外液過剰量算出装置 | |
Vega et al. | Body composition affects urea distribution volume estimated by Watson's formula | |
JP2022160220A (ja) | 細胞外液量標準化装置、これを備える細胞外液量評価装置及び細胞外液量を標準化するためのコンピュータプログラム | |
Guo et al. | A13381 The relationship between blood pressure components of Ambulatory blood pressure monitoring and cystatin C in essential hypertensive patients | |
Aspromonte et al. | Bioimpedance Vectorial Analyses in Cardiorenal Syndrome | |
JP2022524525A (ja) | 透析患者における物質の生成速度の推定 | |
Lin et al. | THE (PRO) RENIN RECEPTOR IS INVOLVED IN KIDNEY ORGANOID DEVELOPMENT | |
Anastasiou et al. | CHANGES ON LEFT VENTRICULAR FUNCTION AND CHARACTERISTICS ACCORDING TO THE DEGREE OF INTERDIALYTIC WEIGHT GAIN IN MAINTENANCE HEMODIALYSIS PATIENTS | |
Aziza | A13793 Epidemiological Profile of Patients Undergoing Hemodialysis Twice per Week in Top National Referral General Hospital in Jakarta 2017 | |
Guo et al. | A13373 A study on the reproducibility of measurement of aortic cross-sectional distensibility of patients with essential hypertension by MR imaging | |
Tuy et al. | Fluid-volume assessment in the investigation of acute heart failure | |
Burlacu | Dimitrie Siriopol, Luminita Voroneanu, Simona Hogas, Mugurel Apetrii, Angelica Gramaticu, Raluca Dumea | |
Huybrechts et al. | 8.5 Carotid to Femoral Pulse Wave Velocity: Which Distance, Obtained by Tape Measure, Corresponds Best with the Real Travelled Aortic Path Length? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200630 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211011 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230220 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230404 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230417 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7276155 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |